Stifel Nicolaus analyst Paul Matteis maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of $430.00. The company’s shares closed yesterday at $397.58.
According to TipRanks, Matteis is a 4-star analyst with an average return of 6.4% and a 45.68% success rate. Matteis covers the Healthcare sector, focusing on stocks such as Neurogene, Dyne Therapeutics, and ACADIA Pharmaceuticals.
Vertex Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $458.39, implying a 15.30% upside from current levels. In a report released on April 8, RBC Capital also maintained a Hold rating on the stock with a $417.00 price target.
The company has a one-year high of $448.40 and a one-year low of $316.43. Currently, Vertex Pharmaceuticals has an average volume of 1.28M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Vertex Pharmaceuticals (VRTX) Company Description:
Based in Massachusetts and incorporated in 1989, Vertex Pharmaceuticals, Inc. is a biopharmaceutical company, which is engaged in the development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
Read More on VRTX:
- M&A: Vertex Bolsters its Drug Portfolio with Alpine Deal
- RBC says pain opinion leader ‘notably negative’ on Vertex’s VX-548
- Truist pharmaceuticals analyst holds an analyst/industry conference call
- Vertex announces acceptance of NDS for exagamglogene autotemcel
- Vertex Pharmaceuticals advances inaxaplin into Phase 3 portion of trial
